A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Stopped early · Phase 2
Conditions studied: ALSP
In brief
This is a multicenter, open-label study to assess the safety and tolerability of iluzanebart (also referred to as VGL101) in subjects with documentation of a gene mutation in the CSF1R gene for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and to evaluate the effects of iluzanebart on imaging and biomarkers of disease progression in subjects with ALSP. Participants will receive infusions of iluzanebart approximately every 4 weeks for 1 year. The study includes a 52-week, open-label Core Study, followed by a Long-Term Extension (LTE), which provides subjects who complete the original 52-week study (Core Study) with the option to continue treatment for up to an additional 2 years.
Key facts
- Study ID
- NCT05677659
- Run by
- Vigil Neuroscience, Inc.
- People needed
- 20
- Starts
- 2022-12-14
- Expected to finish
- 2025-06-04
- Last updated by the study team
- 2025-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigative Site 3 — San Francisco, California, United States
- Investigative Site 2 — Englewood, Colorado, United States
- Investigative Site 1 — Jacksonville, Florida, United States
- Investigative Site 5 — Boston, Massachusetts, United States
- Investigative Site 6 — Philadelphia, Pennsylvania, United States
- Investigative Site 10 — Paris, France
- Investigative Site 7 — Leipzig, Germany
- Investigative Site 9 — Tübingen, Germany
- Investigative Site 8 — Amsterdam, Netherlands
- Investigative Site 4 — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.